智通财经APP讯，翰思艾泰-B(03378)发布公告，公司已启动自主研发的候选药物HX111(一款OX40靶向抗体偶联药物(ADC)候选药物)针对复发难治性淋巴瘤及实体瘤的Ⅰ期临床试验，已于近期顺利完成首例患者入组给药。
HX111可高亲和、高特异性地结合肿瘤细胞表面的OX40分子，并能高效地经内吞作用进入肿瘤细胞后，由溶酶体蛋白酶裂解连接子，释放强效有效载荷，进而诱导肿瘤细胞凋亡。OX40分子在部分淋巴瘤及实体瘤中呈高表达特征，这类肿瘤目前缺乏有效的治疗手段，存在显著的未满足临床需求。公司研发的HX111，是全球范围内已公开进入临床阶段的首款OX40靶向ADC药物(全球首创，First-in-Class，FIC)。该领域目前仍处于早期探索阶段，HX111具备显著的先发优势，未来有望填补此类肿瘤治疗领域的空白。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.